74 related articles for article (PubMed ID: 28579832)
1. APF530 versus ondansetron, each in a guideline-recommended three-drug regimen, for the prevention of chemotherapy-induced nausea and vomiting due to anthracycline plus cyclophosphamide-based highly emetogenic chemotherapy regimens: a post hoc subgroup analysis of the Phase III randomized MAGIC trial.
Schnadig ID; Agajanian R; Dakhil C; Gabrail N; Vacirca J; Taylor C; Wilks S; Braun E; Mosier MC; Geller RB; Schwartzberg L; Vogelzang N
Cancer Manag Res; 2017; 9():179-187. PubMed ID: 28579832
[TBL] [Abstract][Full Text] [Related]
2. Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: results of a randomized, double-blind phase III trial.
Weinstein C; Jordan K; Green SA; Camacho E; Khanani S; Beckford-Brathwaite E; Vallejos W; Liang LW; Noga SJ; Rapoport BL
Ann Oncol; 2016 Jan; 27(1):172-8. PubMed ID: 26449391
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics, safety, and efficacy of APF530 (extended-release granisetron) in patients receiving moderately or highly emetogenic chemotherapy: results of two Phase II trials.
Gabrail N; Yanagihara R; Spaczyński M; Cooper W; O'Boyle E; Smith C; Boccia R
Cancer Manag Res; 2015; 7():83-92. PubMed ID: 25834466
[TBL] [Abstract][Full Text] [Related]
4. Resource Utilization for Chemotherapy-Induced Nausea and Vomiting Events in Patients with Solid Tumors Treated with Antiemetic Regimens.
Schwartzberg L; Harrow B; Lal LS; Radtchenko J; Lyman GH
Am Health Drug Benefits; 2015; 8(5):273-82. PubMed ID: 26380034
[TBL] [Abstract][Full Text] [Related]
5. Rikkunshito for Preventing Chemotherapy-Induced Nausea and Vomiting in Lung Cancer Patients: Results from 2 Prospective, Randomized Phase 2 Trials.
Harada T; Amano T; Ikari T; Takamura K; Ogi T; Fujikane T; Fujita Y; Taima K; Tanaka H; Sasaki T; Okumura S; Sugawara S; Yokouchi H; Yamada N; Morikawa N; Dosaka-Akita H; Isobe H; Nishimura M
Front Pharmacol; 2017; 8():972. PubMed ID: 29387008
[TBL] [Abstract][Full Text] [Related]
6. CT-P6 compared with reference trastuzumab for HER2-positive breast cancer: a randomised, double-blind, active-controlled, phase 3 equivalence trial.
Stebbing J; Baranau Y; Baryash V; Manikhas A; Moiseyenko V; Dzagnidze G; Zhavrid E; Boliukh D; Stroyakovskii D; Pikiel J; Eniu A; Komov D; Morar-Bolba G; Li RK; Rusyn A; Lee SJ; Lee SY; Esteva FJ
Lancet Oncol; 2017 Jul; 18(7):917-928. PubMed ID: 28592386
[TBL] [Abstract][Full Text] [Related]
7. Long-term follow-up of chemoimmunotherapy with rituximab, oxaliplatin, cytosine arabinoside, dexamethasone (ROAD) in patients with relapsed CD20+ B-cell non-Hodgkin lymphoma: Results of a study of the Mayo Clinic Cancer Center Research Consortium (MCCRC) MC0485 now known as academic and community cancer research united (ACCRU).
Witzig TE; Johnston PB; LaPlant BR; Kurtin PJ; Pederson LD; Moore DF; Nabbout NH; Nikcevich DA; Rowland KM; Grothey A
Am J Hematol; 2017 Oct; 92(10):1004-1010. PubMed ID: 28614905
[TBL] [Abstract][Full Text] [Related]
8. Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial.
Cameron D; Morden JP; Canney P; Velikova G; Coleman R; Bartlett J; Agrawal R; Banerji J; Bertelli G; Bloomfield D; Brunt AM; Earl H; Ellis P; Gaunt C; Gillman A; Hearfield N; Laing R; Murray N; Couper N; Stein RC; Verrill M; Wardley A; Barrett-Lee P; Bliss JM;
Lancet Oncol; 2017 Jul; 18(7):929-945. PubMed ID: 28600210
[TBL] [Abstract][Full Text] [Related]
9. A phase Ib study of pembrolizumab plus chemotherapy in patients with advanced cancer (PembroPlus).
Weiss GJ; Waypa J; Blaydorn L; Coats J; McGahey K; Sangal A; Niu J; Lynch CA; Farley JH; Khemka V
Br J Cancer; 2017 Jun; 117(1):33-40. PubMed ID: 28588322
[TBL] [Abstract][Full Text] [Related]
10. Combination of cationic dexamethasone derivative and STAT3 inhibitor (WP1066) for aggressive melanoma: a strategy for repurposing a phase I clinical trial drug.
Sau S; Mondal SK; Kashaw SK; Iyer AK; Banerjee R
Mol Cell Biochem; 2017 Dec; 436(1-2):119-136. PubMed ID: 28585089
[TBL] [Abstract][Full Text] [Related]
11. Kinetic-Pharmacodynamic Model of Chemotherapy-Induced Peripheral Neuropathy in Patients with Metastatic Breast Cancer Treated with Paclitaxel, Nab-Paclitaxel, or Ixabepilone: CALGB 40502 (Alliance).
Mehrotra S; Sharma MR; Gray E; Wu K; Barry WT; Hudis C; Winer EP; Lyss AP; Toppmeyer DL; Moreno-Aspitia A; Lad TE; Valasco M; Overmoyer B; Rugo H; Ratain MJ; Gobburu JV
AAPS J; 2017 Sep; 19(5):1411-1423. PubMed ID: 28620884
[TBL] [Abstract][Full Text] [Related]
12. Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial.
Cortés J; Rugo HS; Awada A; Twelves C; Perez EA; Im SA; Gómez-Pardo P; Schwartzberg LS; Diéras V; Yardley DA; Potter DA; Mailliez A; Moreno-Aspitia A; Ahn JS; Zhao C; Hoch U; Tagliaferri M; Hannah AL; O'Shaughnessy J
Breast Cancer Res Treat; 2017 Sep; 165(2):329-341. PubMed ID: 28612225
[TBL] [Abstract][Full Text] [Related]
13. TAK-228 (formerly MLN0128), an investigational dual TORC1/2 inhibitor plus paclitaxel, with/without trastuzumab, in patients with advanced solid malignancies.
Burris HA; Kurkjian CD; Hart L; Pant S; Murphy PB; Jones SF; Neuwirth R; Patel CG; Zohren F; Infante JR
Cancer Chemother Pharmacol; 2017 Aug; 80(2):261-273. PubMed ID: 28601972
[TBL] [Abstract][Full Text] [Related]
14. Sequential administration of XELOX and XELIRI is effective, feasible and well tolerated by patients with metastatic colorectal cancer.
Fukui T; Suzuki K; Ichida K; Takayama Y; Kakizawa N; Muto Y; Hasegawa F; Watanabe F; Kikugawa R; Saito M; Tsujinaka S; Miyakura Y; Rikiyama T
Oncol Lett; 2017 Jun; 13(6):4947-4952. PubMed ID: 28599498
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of postoperative bio-chemoradiotherapy using cetuximab and docetaxel for high-risk head and neck cancer patients in Japan.
Nishimura G; Shiono O; Sano D; Yabuki K; Arai Y; Chiba Y; Tanabe T; Oridate N
Cancer Chemother Pharmacol; 2017 Jul; 80(1):203-207. PubMed ID: 28597041
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and Safety of Pertuzumab and Trastuzumab Administered in a Single Infusion Bag, Followed by Vinorelbine: VELVET Cohort 2 Final Results.
Andersson M; López-Vega JM; Petit T; Zamagni C; Easton V; Kamber J; Restuccia E; Perez EA
Oncologist; 2017 Oct; 22(10):1160-1168. PubMed ID: 28592618
[TBL] [Abstract][Full Text] [Related]
17. Impact of concomitant dexamethasone dosing schedule on bortezomib-induced peripheral neuropathy in multiple myeloma.
Kumar SK; Laubach JP; Giove TJ; Quick M; Neuwirth R; Yung G; Rajkumar SV; Richardson PG
Br J Haematol; 2017 Sep; 178(5):756-763. PubMed ID: 28591409
[TBL] [Abstract][Full Text] [Related]
18. Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a network meta-analysis.
Piechotta V; Adams A; Haque M; Scheckel B; Kreuzberger N; Monsef I; Jordan K; Kuhr K; Skoetz N
Cochrane Database Syst Rev; 2021 Nov; 11(11):CD012775. PubMed ID: 34784425
[TBL] [Abstract][Full Text] [Related]
19. Phase IIIb Safety and Efficacy of Intravenous NEPA for Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Patients with Breast Cancer Receiving Initial and Repeat Cycles of Anthracycline and Cyclophosphamide (AC) Chemotherapy.
Schwartzberg L; Navari R; Clark-Snow R; Arkania E; Radyukova I; Patel K; Voisin D; Rizzi G; Wickham R; Gralla RJ; Aapro M; Roeland E
Oncologist; 2020 Mar; 25(3):e589-e597. PubMed ID: 32162813
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
